Reneuron Regulatory News (RENE)

RNS REACH

ReNeuron Group plc

("ReNeuron" or the "Company")

Senior business development appointment

ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, announces the appointment of Nicholas Adams in the newly created role of VP Business Development & Alliance Management.

His appointment reflects the continued clinical progress at the Company, the current and anticipated level of interest from potential licensing partners in the Company's programmes and the importance of the ongoing management of licensing and other agreements once signed.

Nick has considerable experience leading a range of international deal types including in- and out-licensing, divestments, spin-outs and mergers and acquisitions. He has a BSc in biology and law qualifications, with 30 years' experience in the pharmaceutical and biotechnology industries. His early career was in clinical development, at companies including Ciba-Geigy (now Novartis), Cephalon and Eisai, after which he moved into business development. Nick was Vice-President, Business Development at Antisoma plc, where more than US$160m was raised through licensing deals and divestments. More recently, he has served as Chief Business Officer at Clavis Pharma ASA and then Redx Pharma plc.

Olav Hellebø, Chief Executive Officer of ReNeuron, commented: 

"I'm delighted to welcome Nick Adams to ReNeuron's executive team. He will strengthen our business development capabilities and also be a dedicated resource for managing current and future licensing agreements. As highlighted in recent announcements, business development has become an increasingly important aspect of the Company's activities as we pursue discussions with commercial third parties regarding potential collaboration and/or out-licensing deals across our programmes."

ENDS

ENQUIRIES:

About ReNeuron

ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com.